Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, to its participation in the upcoming World Conference on Lung Cancer (“WCLC”) of the International Association for the Study of Lung Cancer (“IASLC”), taking place in Seoul, Republic of Korea, from September 12 to 15, 2026.
At the meeting, NMS will present a scientific poster featuring its proprietary PARP7 inhibitor, atamparib.
Title: “A Phase Ib/II Study of Atamparib, a PARP7 Inhibitor, in Patients with Advanced Solid Tumors”
Presenter: Dr. Xinru Chen, Shanghai East Hospital
Poster Section: Clinical Trials in Progress
Poster Board Number: P2-372
Abstract Control Number: 606
Date & Time: Monday, September 14, 2026 at 10:30 AM KST / UTC +9
Link to full poster abstract: https://cattendee.abstractsonline.com/meeting/21487/Session/217
This ongoing phase 1b/2 trial is evaluating atamparib, a potential, orally bioavailable, selective PARP7 inhibitor. Through its unique dual mechanism of action, atamparib disrupts KRAS-driven and other oncogenic signaling pathways, while activating innate immune responses. The study is currently exploring higher dose levels and generating proof-of-concept data in selected patients with advanced or metastatic NSCLC adenocarcinoma.
We look forward to engaging with the scientific community at the IASLC 2026 WCLC and sharing insights from our work.
About Atamparib
Atamparib was acquired by NMS from Ribon Therapeutics in November 2024 (previously RBN 2397/ONO 7119). It has demonstrated a favorable tolerability profile in prior Phase I/II clinical evaluation (NCT04053673, NCT05127590, JRCT2031210373). Supported by new preclinical data and early signs of clinical activity, NMS is advancing atamparib for the treatment of advanced or metastatic solid tumors, with the goal of addressing significant unmet medical needs as a single agent and in combination regimens.